Leg ulcers in patients with β-thalassaemia intermedia: A single centre's experience

dc.contributor.authorMatta, Bassem N.
dc.contributor.authorAbbas, Ossama M.
dc.contributor.authorMaakaron, Joseph E.
dc.contributor.authorKoussa, Suzanne C.
dc.contributor.authorDaderian, Rita H.
dc.contributor.authorTaher, Ali T.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentDermatology
dc.contributor.departmentDivision of Hematology Oncology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:42:57Z
dc.date.available2025-01-24T11:42:57Z
dc.date.issued2014
dc.description.abstractBackground: Leg ulcers in β-thalassaemia intermedia (TI) patients are a relatively common occurrence that have an 8% prevalence. Both the pathophysiology and treatment of this condition have not been well-elucidated. This is mainly because of the rarity of the disease and the lack of well-structured studies. The goal of this study was to better explore the risk factors for the development of this condition along with the treatment options available. Methods: We present 11 such cases that have occurred in 6 β-TI patients over the course of 19 years who are followed up at the Chronic Care Center of Lebanon. Results: Our patient population comprised three men and three women aged between 25 and 58, most of whom had iron overload and with an average lifetime haemoglobin ranging between 49 g/L and 77 g/L. Most of the patients were treated with blood transfusions with varying degrees of success. Nonetheless, some received Hydroxyurea, granulocyte macrophage colony-stimulating factor (GM-CSF) or topical antibiotics. Conclusion: Our results show that chelation therapy, hydroxyurea use and blood transfusions are beneficial in the treatment of this condition. Whether foetal haemoglobin is directly related to the development of the ulcers is not clear based on our results. Larger studies are needed to better explore the risk factors that predispose patients to this condition. © 2013 European Academy of Dermatology and Venereology.
dc.identifier.doihttps://doi.org/10.1111/jdv.12211
dc.identifier.eid2-s2.0-84906934291
dc.identifier.pmid23848223
dc.identifier.urihttp://hdl.handle.net/10938/30147
dc.language.isoen
dc.publisherBlackwell Publishing Ltd
dc.relation.ispartofJournal of the European Academy of Dermatology and Venereology
dc.sourceScopus
dc.subjectAdult
dc.subjectBeta-thalassemia
dc.subjectFemale
dc.subjectHumans
dc.subjectLeg ulcer
dc.subjectMale
dc.subjectMiddle aged
dc.subjectRetrospective studies
dc.subjectRisk factors
dc.subjectAntibiotic agent
dc.subjectGranulocyte macrophage colony stimulating factor
dc.subjectHemoglobin
dc.subjectHydroxyurea
dc.subjectArticle
dc.subjectBeta thalassemia
dc.subjectBeta thalassemia intermedia
dc.subjectBlood transfusion
dc.subjectChelation therapy
dc.subjectClinical article
dc.subjectHuman
dc.subjectLebanon
dc.subjectPathophysiology
dc.subjectPriority journal
dc.subjectRisk factor
dc.subjectThalassemia intermedia
dc.subjectComplication
dc.subjectRetrospective study
dc.titleLeg ulcers in patients with β-thalassaemia intermedia: A single centre's experience
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2014-10744.pdf
Size:
103.17 KB
Format:
Adobe Portable Document Format